1. Bollerslev J, et al. European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults. Eur J Endocrinol. 2015 Aug;173(2):G1-20.
  2. Brandi ML, et al. Management of Hypoparathyroidism: Summary Statement and Guidelines. The Journal of Clinical Endocrinology & Metabolism. 2016 Jun 1;101(6):2273–83.
  3. Chen K, et al. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review. Journal of Medical Economics. 2019 Jun 17;22(11):1141–52.
  4. Mannstadt M, et al. Hypoparathyroidism. Nat Rev Dis Primers. 2017 Aug 31;3:17055.
  5. Clarke BL, et al. Epidemiology and Diagnosis of Hypoparathyroidism. J Clin Endocrinol Metab. 2016 Jun 1;101(6):2284–2299.
  6. Khan AA, et al. Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. Eur J Endocrinol. 2019 Mar 01;180(3):1-22.
  7. Ascendis Pharma UK. Data on file. 2025.
  8. Shoback DM, et al. J Clin Endocrinol Metab. 2016;101(6):2300–12.
  9. National Cancer Institute. Bone Density. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/bone-density. [accessed October 2025].
  10. Medline Plus. Calcification. Available from: https://medlineplus.gov/ency/article/002321.htm [accessed October 2025].
  11. National Cancer Institute. Cognitive impairment. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cognitive-impairment. [accessed October 2025].
  12. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: The National Academies Press; 2011.
  13. Qadeer HA, Bashire K. Physiology, Phosphate. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560925/. [accessed October 2025].
  14. Goyal A, et al. Hypocalcemia. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430912/. [accessed October 2025].
  15. Goyal R, Jialal I. Hyperphosphatemia. StatPearls. 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551586/. [accessed October 2025].
  16. National Cancer Institute. Renal Failure. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/renal-failure. [accessed October 2025].
  17. Brod M, et al. Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Qual Life Res. 2021 Jan;30(1):277-291. doi: 10.1007/s11136-020-02607-1. Epub 2020 Aug 24. PMID: 32833143; PMCID: PMC7847873.
  18. Kontogeorgos G, et al. Low health-related quality of life in hypoparathyroidism and need for PTH analog. Endocrine Connections. 2022 Jan 10;11(1).
  19. Ascendis Pharma UK. Data on file. 2024.

Living with hypoparathyroidism

Woman in a garden

Impact of hypoparathyroidism on quality of life, physical functioning and psychological wellbeing

The burden of hypoparathyroidism (also known as hypopara) negatively impacts health-related quality of life, physical functioning, and psychological well-being, regardless of serum calcium levels. 2, 17, 18

Tab 1 content.

Tab 2 content.

Impact on quality of life

In a survey of 42 people living with hypopara, the respondents reported the following impacts on their daily life, mental health, activity and social life & relationships. 17

Daily Life 17

79%

were not able to do as many things around the home

43%

said that hypopara interferes with their ability to work

67%

were unable to do as much as they used to/want to

Mental Health 17

81%

felt anxious or had anxiety

64%

felt frustrated

62%

felt depressed or sad

Activity 17

76%

were not able to exercise in the same way

52%

are less active than they used to be/want to be

50%

were not as mobile (including ability to walk)

Social Life & Relationships 17

79%

were less able to engage in social activities

57%

were limited in the types of social activities they could do

43%

said hypopara affected their relationships with family

Find out more about living with hypopara

The insights used to inform this video have been taken from the qualitative responses gathered from a patient survey conducted in partnership with Ascendis Pharma UK and Parathyroid UK in 2024. 19 Data was reported on an aggregate level and data was provided anonymously.